ziltivekimab

Novo Nordisk announced on Friday that its experimental anti-inflammatory drug ziltivekimab failed to reduce the risk of major adverse cardiovascular events in the Phase 3 ZEUS trial, sending shares of the Danish drugmaker down 10% in premarket trading.